Acorda discontinues PD candidate tozadenant

Acorda Therapeutics Inc. (NASDAQ: ACOR) discontinued development of Parkinson's disease candidate tozadenant (SYN115) "based on new information" related to cases of agranulocytosis disclosed

Read the full 238 word article

User Sign In